The Eyes Have It For Topical Flurbiprofen It reduces ocular inflammation after argon laser trabeculoplasty This study investigated the effect of topical flurbiprofen on the postoperative inflammatory response to argon laser trabeculoplasty and on intraocular pressure (lOP) following the same procedure. 63 patients requiring this treatment for primary open-angle glaucoma in 1 eye received 1 drop of flurbiprofen sodium 0.03% every 20 min for the 2 hours before laser therapy and 1 drop immediately and then 4 hourly afterwards, for 7 days. 55 similar patients received placebo drops on the same schedule. More men than women received placebo than flurbiprofen and more older patients received flurbiprofen than placebo. All patients had baseline lOPs greater than or equal to 15mm Hg. Treatments were given in a double-blind and randomised fashion. No significant differences between groups were found in postoperative lOPs. However, 24 hours after laser therapy the flurbiprofen group had significantly less conjunctival erythema, and significantly less uncontrolled inflammation (anterior chamber cells and flare) at the end of the study period. Investigations into other concentrations, dosages, or administration schedules of topical flurbiprofen seem warranted. Weinreb, R.N.; Robin, A.L.; 8aerveldt, G.; Drake, M. V.; Blumenthal, M. et al.: Archives of Ophthalmology 102: 1629-1632 (Nov 1984) 10 INPHARMA® 2 Feb 1985 0156_2703/85/0202-0010/0$01.00/0 © ADIS Press

The Eyes Have It For Topical Flurbiprofen

Download PDF Report

Upload
dangnguyet
View
214
Download
2

Embed Size (px)

Citation preview

The Eyes Have It For Topical Flurbiprofen

It reduces ocular inflammation after argon laser trabeculoplasty This study investigated the effect of topical flurbiprofen on the postoperative inflammatory response to

argon laser trabeculoplasty and on intraocular pressure (lOP) following the same procedure. 63 patients requiring this treatment for primary open-angle glaucoma in 1 eye received 1 drop of flurbiprofen sodium 0.03% every 20 min for the 2 hours before laser therapy and 1 drop immediately and then 4 hourly afterwards, for 7 days. 55 similar patients received placebo drops on the same schedule. More men than women received placebo than flurbiprofen and more older patients received flurbiprofen than placebo. All patients had baseline lOPs greater than or equal to 15mm Hg. Treatments were given in a double-blind and randomised fashion.

No significant differences between groups were found in postoperative lOPs. However, 24 hours after laser therapy the flurbiprofen group had significantly less conjunctival erythema, and significantly less uncontrolled inflammation (anterior chamber cells and flare) at the end of the study period. Investigations into other concentrations, dosages, or administration schedules of topical flurbiprofen seem warranted. Weinreb, R.N.; Robin, A.L.; 8aerveldt, G.; Drake, M. V.; Blumenthal, M. et al.: Archives of Ophthalmology 102: 1629-1632 (Nov 1984)

10 INPHARMA® 2 Feb 1985 0156_2703/85/0202-0010/0$01.00/0 © ADIS Press